Stellenbosch University

Cheryl Baxter

Head Scientific Support (Health sciences)


  • Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis
  • HPV infection and the genital cytokine milieu in women at high risk of HIV acquisition
  • Identifying SARS-CoV-2 infections in South Africa: Balancing public health imperatives with saving lives
  • The use of PSA as a biomarker of recent semen exposure in female reproductive health studies
  • COVID-19 in Africa: Catalyzing change for sustainable development
  • COVID-19: Impact on the HIV and Tuberculosis Response, Service Delivery, and Research in South Africa
  • Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis
  • Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa.
  • The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance
  • SARS-CoV-2 Africa dashboard for real-time COVID-19 information
  • Molecular Epidemiology and Diversity of SARS-CoV-2 in Ethiopia, 2020–2022
  • Managing and assembling population-scale data streams, tools and workflows to plan for future pandemics within the INFORM-Africa Consortium
  • Urgent need for a non-discriminatory and non-stigmatizing nomenclature for monkeypox virus.
  • Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial
  • HIV pre-exposure prophylaxis implementation in Africa: some early lessons
  • Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials
  • Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study
  • Evaluation of miniaturized Illumina DNA preparation protocols for SARS-CoV-2 whole genome sequencing
  • Trends in HIV Prevention, Treatment, and Incidence in a Hyperendemic Area of KwaZulu-Natal, South Africa
  • Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: Study protocol for the CAPRISA 012A randomised controlled phase I trial
  • Semen IgM, IgG1, and IgG3 Differentially Associate With Pro-Inflammatory Cytokines in HIV-Infected Men
  • Global Expansion of SARS-CoV-2 Variants of Concern: Dispersal Patterns and Influence of Air Travel
  • The genital tract and rectal microbiomes: their role in HIV susceptibility and prevention in women
  • Mechanisms of sexually transmitted infection-induced inflammation in women: implications for HIV risk
  • Impact of SARS-CoV-2 variants of concern on Covid-19 epidemic in South Africa
  • Continued Emergence and Evolution of Omicron in South Africa: New BA.4 and BA.5 lineages
  • HIV incidence rates in adolescent girls and young women in sub-Saharan Africa
  • Prevention of HIV in adolescent girls and young women: Key to an AIDS-free generation
  • The dual burden of gender-based violence and HIV in adolescent girls and young women in South Africa
  • Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: Study protocol for the first-in-human CAPRISA 012B phase i clinical trial
  • Improving adolescent maternal health
  • Molecular Epidemiology and Diversity of SARS-CoV-2 in Ethiopia, 2020-2022
  • Clinical trials of broadly neutralizing monoclonal antibodies for human immunodeficiency virus prevention: A review
  • Antibodies for HIV prevention in young women
  • Genital Inflammation and the Risk of HIV Acquisition in Women
  • Higher Mucosal Antibody Concentrations in Women with Genital Tract Inflammation
  • Seroprevalence of hepatitis B virus: Findings from a population-based household survey in KwaZulu-Natal, South Africa
  • Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women
  • CAPRISA 018: A phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women
  • HIV incidence trends in Africa: young women at highest risk
  • Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention
  • Comparing SARS-CoV-2 sequencing methodologies during early phase detection of the Delta variant in South Africa
  • The microbiome and HIV prevention strategies in women
  • Combination HIV prevention options for young women in Africa
  • Dispersal patterns and influence of air travel during the global expansion of SARS-CoV-2 variants of concern
  • Recent Semen Exposure Impacts the Cytokine Response and Bacterial Vaginosis in Women
  • Viral suppression among pregnant adolescents and women living with HIV in rural KwaZulu-Natal, South Africa: a cross sectional study to assess progress towards UNAIDS indicators and Implications for HIV Epidemic Control
  • Higher mucosal antibody concentrations in women with genital tract inflammation
  • Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial
  • Translating pre-exposure prophylaxis evidence into practice and public health impact
  • Microbicides & their implications in HIV prevention
  • Overview of the book
  • Introduction
  • New prevention strategies under development and investigation
  • Integration of antiretroviral therapy with tuberculosis treatment
  • PRO 2000: Next steps for microbicide development
  • Tenofovir gel for the prevention of herpes simplex virus type 2 infection
  • Utilizing nucleic acid amplification to identify acute HIV infection [4]
  • Antiretroviral prophylaxis for the prevention of HIV infection: Future implementation challenges
  • Antiretroviral therapy: Challenges and options in South Africa [3]
  • The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis.
  • Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial
  • Preventing HIV infection in women: A global health imperative
  • Global Epidemiology of HIV-AIDS
  • Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: Study protocol for an open-label randomized controlled trial
  • Adherence in the CAPRISA 004 tenofovir gel microbicide trial
  • Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa
  • Microbicides for prevention of HIV infection: Clinical efficacy trials
  • Topical microbicides-What's new?
  • Recruitment of high risk women for HIV prevention trials: Baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial
  • Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women
  • When to start antiretroviral therapy during tuberculosis treatment?
  • Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies
  • The need for multipurpose prevention technologies in sub-Saharan Africa
  • Safety of tenofovir gel, a vaginal microbicide, in South African women: Results of the CAPRISA 004 Trial
  • Overview of microbicides for the prevention of human immunodeficiency virus
  • Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: Results from the CAPRISA 004 trial
  • Timing of initiation of antiretroviral drugs during tuberculosis therapy
  • A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection
  • Microbicides for the prevention of sexually transmitted HIV infection
  • Strengthening HIV services for pregnant women: An opportunity to reduce maternal mortality rates in Southern Africa/sub-Saharan Africa

Usage metrics

Co-workers & collaborators

Tulio de Oliveira

Tulio de Oliveira

Cheryl Baxter's public data